ALPN-202 With PD-1 Inhibition in Advanced Malignancies

Active:	No
Cancer Type:	Hodgkin Lymphoma Lymphoma Non-Hodgkin Lymphoma	NCT ID:	NCT04920383
Trial Phases:	Phase I	Protocol IDs:	AIS-B02 (primary) NCI-2021-08960
Eligibility:	18 - 80 Years, Male and Female	Study Type:	Treatment
Study Sponsor:	Alpine Immune Sciences, Inc.
NCI Full Details:	http://clinicaltrials.gov/show/NCT04920383

Summary

This is a cohort-based, open-label dose escalation and expansion study in adults with
advanced solid tumors or lymphoma.

Treatment Sites in Georgia

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
404-778-5180
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.